GlassScriptPhysician profile
Usman Latif
NPI 1750443313
$733,714.24
in general payments reported to CMS, 2019-2025
19 companies · $224K in 2025
The $224K reported for 2025 was more than what 99% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,886 · 2020: $387 · 2021: $509 · 2022: $45K · 2023: $177K · 2024: $284K · 2025: $224K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $463K · Travel and Lodging: $87K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $72K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Food and Beverage: $22K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $463,395.57 |
| Travel and Lodging | $86,548.66 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $72,105.09 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,212.50 |
| Food and Beverage | $21,702.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $237,807.48 | 2019-2024 | Senza, Omnia, Vyrsa V1 |
| Nalu Medical, INC. | $166,704.36 | 2020-2025 | Nalu Neurostimulation System |
| Spinal Simplicity, LLC | $81,354.36 | 2022-2025 | Ha Minuteman G3-R, Liberty Si, Patriot Si |
| Spr Therapeutics, INC | $79,702.39 | 2019-2025 | Sprint Pns System |
| Globus Medical, INC. | $56,122.76 | 2025 | Senza, Vyrsa V1, Affirm |
| Saluda Medical Americas, INC. | $46,132.86 | 2024-2025 | Evoke |
| Vertos Medical, INC. | $43,265.61 | 2022-2024 | Mild Device Kit |
| Omnia Medical, LLC | $11,000.00 | 2022-2023 | |
| Abbott Laboratories | $10,407.84 | 2021-2025 | Proclaim, Eterna |
| Mml US, INC. | $238.09 | 2024 | Reactiv8 |
| Cook Medical LLC | $210.07 | 2023-2024 | Hemospray |
| Medtronic, INC. | $191.92 | 2022-2023 | Synchromedii |
| Curonix LLC | $146.87 | 2022-2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Painteq LLC | $122.11 | 2024 | Painteq |
| Stimwave Technologies Incorporated | $116.99 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $93.55 | 2020-2025 | Wavewriter Alpha Prime 16 |
| Vertex Pharmaceuticals Incorporated | $45.78 | 2025 | |
| Pfizer INC. | $27.16 | 2020 | |
| Hydrocision, INC. | $24.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,466.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usman Latif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.